YiLin

Shijiazhuang Yiling Pharmaceutical is a prominent Chinese pharmaceutical company specializing in the research, development, and manufacturing of Traditional Chinese Medicine (TCM) and innovative chemical drugs. Founded in 1992 by Academician Wu Yiling, the company operates on the unique "TCM Collateral Theory" (Luo Bing Theory), which integrates traditional wisdom with modern evidence-based medicine to guide drug discovery. Its flagship products include Lianhua Qingwen for respiratory health and Tongxinluo for cardiovascular diseases, both of which have achieved significant commercial success and clinical recognition. Beyond TCM, Yiling has expanded its portfolio into chemical drugs, healthcare products, and international markets, maintaining a robust pipeline focused on chronic and metabolic diseases.